¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ) 2022 ´ëÇÑÀÓ»ó¾à¸®ÇÐȸ Ãá°èÇмú´ëȸ : 2022-04-29

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ) 2022 ´ëÇÑÀÓ»ó¾à¸®ÇÐȸ Ãá°èÇмú´ëȸ : 2022-04-29
±³À°ÀÏÀÚ : 2022-04-29
±³À°Àå¼Ò : ¿Â¶óÀΠ 
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ) 2022 ´ëÇÑÀÓ»ó¾à¸®ÇÐȸ Ãá°èÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇÑÀÓ»ó¾à¸®ÇÐȸ
´ã´çÀÚ : ¹Ú¼Ò¹Î
¿¬¶ôó : 02-398-5055  
À̸ÞÀÏ : office@kscpt.org      
±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¸¶ÃëÅëÁõÀÇÇаú, Áø´Ü°Ë»çÀÇÇаú, º´¸®°ú, °¡Á¤ÀÇÇаú, ÇÙÀÇÇаú, ÀÀ±ÞÀÇÇаú¿¹¹æÀÇÇÐ, ¾à¸®ÇÐ
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 4Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã 
±³À°½Ã°£ : 4 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 120,000¿ø      
ºñ°í ¿Â¶óÀÎ Âü¼® : Á¤È¸¿ø 5¸¸¿ø, ÁØȸ¿ø 2¸¸¿ø / ºñȸ¿ø ÀÏ¹Ý 10¸¸¿ø, ºñȸ¿ø Çлý 5¸¸¿ø  ÇöÀåÂü¼® : Á¤È¸¿ø 7¸¸¿ø, ÁØȸ¿ø 4¸¸¿ø / ºñȸ¿ø ÀÏ¹Ý 12¸¸¿ø, ºñȸ¿ø Çлý 8¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-29 ¿Â¶óÀΠ13:00~13:40 Special lecture : Facts and Misconceptions about Aducanumab Approval  Yaning Wang(Createrna Science and Technology) 
±³À°½Ã°£ 04-29 ¿Â¶óÀΠ13:40~14:10 Model guided dose escalation in oncology Phase 1 trial  ±èÀ翬(Novartis Institutes for Biomedical Research (Cambridge MA USA)) 
±³À°½Ã°£ 04-29 ¿Â¶óÀΠ14:10~14:40 Exposure-response relationship for current and future drug development  ¿ÀÀ缺(¼­¿ï´ëÇб³º´¿ø) 
±³À°½Ã°£ 04-29 ¿Â¶óÀΠ14:40~15:10 Recent advances in exposure-response relationship in drug development  ±èÁ¾·ü(ÀÎÁ¦´ë ºÎ»ê¹éº´¿ø) 
Åä·Ð 04-29 ¿Â¶óÀΠ15:10~15:30 Åä·Ð  () 
±³À°½Ã°£ 04-29 ¿Â¶óÀΠ15:30~16:00 Exposure-Response in Cancer: Starting from Genomics  ±è±ÔÇ¥(¿ï»ê´ëÇб³) 
±³À°½Ã°£ 04-29 ¿Â¶óÀΠ16:00~16:30 Experiences to Characterize Exposure-Response Relationship for Various Therapeutics using Modeling and Simulation: Advantages and Challenges  ÇѼºÇÊ(°¡Å縯´ëÇб³) 
±³À°½Ã°£ 04-29 ¿Â¶óÀΠ16:30~17:00 Exposure-Response RelationshipÀ» ÀÌ¿ëÇÑ ½Å¾à°³¹ß °æÇè  ÀÌÁöÀº(LG »ý¸í°úÇÐ) 
Åä·Ð 04-29 ¿Â¶óÀΠ17:00~17:20 Åä·Ð  () 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ) 2022 ´ëÇÑÀÓ»ó¾à¸®ÇÐȸ Ãá°èÇмú´ëȸ : 2022-04-29""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ½ÉÀå´ë»çÁõÈıºÇÐȸ 2022 5th APCMS (Asia-Pacific CardioMetabolic Syndrome) CONGRESS(1ÀÏÂ÷) : 2022-04-29
´ÙÀ½±Û (¿Â¶óÀÎ) ´ëÇÑ»êºÎÀΰúÇÐȸ ¼­¿ï µ¿ºÎÁöȸ ¿ù·ÊÁý´ãȸ : 2022-04-28
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20511 ¼­¿ï ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ 44th Korean College of Rheumatolgy Annual Scientific Meeting and the 18th International Symposium (KCR2024)-ù°³¯ : 2024-05-16 0 0 12:12:26
20510 ºÎ»ê ´ëÇѺñ´¢ÀÇÇÐȸ 310ȸ Çмú´ëȸ(Àü¸³¼± ¾Ï) : 2024-05-16 0 0 12:11:03
20509 ¼­¿ï Á¦ 21 ȸ ´ëÇѳú¿°/³ú¿°ÁõÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-15 0 0 12:09:51
20508 ¼­¿ï (2ÀÏÂ÷) ´ëÇÑÁø´Ü°Ë»çÀÇÇÐȸ 2024³â Ãá°è½ÉÆ÷Áö¾ö : 2024-05-14 0 0 12:08:34
20507 ºÎ»ê ´ëÇÑÁ¤Çü¿Ü°ú ºÎ»ê․¿ï»ê․°æ³²Áöȸ Á¦361Â÷ ¿ù·ÊÇмúȸ : 2024-05-14 0 0 12:06:47
20506 ¼­¿ï ´ëÇÑÀ̺ñÀÎÈÄ°úÀÇ»çȸ 2024 Áöȸ½ÉÆ÷Áö¾ö-¼­¿ï(°­³²) : 2024-05-14 0 0 12:05:35
20505 °æ±â ÇѸ²´ëÇб³¼º½Éº´¿ø Æó ¿¬¼ö°­Á : 2024-05-14 0 0 12:04:15
20504 ¼­¿ï (1ÀÏÂ÷) ´ëÇÑÁø´Ü°Ë»çÀÇÇÐȸ 2024³â Ãá°è½ÉÆ÷Áö¾ö : 2024-05-13 0 0 12:02:26
20503 ´ëÀü Çѱ¹¿©ÀÚÀÇ»çȸ ´ëÀüÁöȸ 5¿ù Çмú½ÉÆ÷Áö¾ö(¾î±ú ÅëÁõÀÇ ¿øÀΰú Ä¡·á) : 2024-05-13 0 0 12:00:55
20502 °æ±â (¿Â¶óÀÎ) Á¦1Â÷ ±ºÆ÷½ÃÀÇ»çȸ Çмú´ëȸ : 2024-05-12 0 0 11:58:37
20501 ¼­¿ï Á¦12ȸ ´ëÇÑÀÓ»ó¼øȯ±âÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-12 0 0 11:57:14
20500 ¼­¿ï 2024 Á¦2Â÷ ´ëÇÑ»êºÎÀΰú³»ºÐºñÇÐȸºÎÀοµ»ó¿¬±¸ Çмú´ëȸ ¹× ¿¬¼ö°­Á : 2024-05-12 0 0 11:56:03
20499 ¼­¿ï Çѱ¹Á¤½ÅÄ¡·áÇÐȸ Á¤½ÅÄ¡·á Áõ·Ê¹ßÇ¥ : 2024-05-11 0 0 11:54:28
20498 ºÎ»ê ¸¸¼ºÆó¼â °ü»óµ¿¸Æ ÁßÀç½Ã¼ú¿¬±¸È¸ The 23rd K-CTO(Korean Chronic Total Occlusion Club) Live Demonstration : 2024-05-11 0 0 11:51:43
20497 ¼­¿ï ´ëÇÑÀü¸³¼±ÇÐȸ The 3rd Korean Prostate Society Prostate Cancer Working Group Symposium : 2024-05-11 0 0 11:21:32
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷